Antiplatelet therapy in type 2 diabetes mellitus
Key result
Antiplatelet therapy reduces morbidity and mortality in patients with diabetes mellitus, although standard regimens may provide inadequate platelet inhibition compared to non-diabetics.
Why the study?
Does antiplatelet therapy reduce ischemic events in patients with type 2 diabetes mellitus?
Population
Patients with type 2 diabetes mellitus
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May support intensified regimens in diabetes; leaves open optimal strategies pending dedicated trials.
Structured PICO
Does antiplatelet therapy reduce ischemic events in patients with type 2 diabetes mellitus?
P
Population
Patients with type 2 diabetes mellitus
I
Intervention
Antiplatelet therapy
O
Outcome
Ischemic events, morbidity, and mortalityhard clinical
Patients with type 2 diabetes may require specific or intensified antiplatelet regimens due to inadequate platelet inhibition achieved with standard therapies.
Cite This Study
Dominick J. Angiolillo (2007) conducted a review in Type 2 diabetes mellitus. Antiplatelet therapy was evaluated. Antiplatelet therapy reduces morbidity and mortality in patients with diabetes mellitus, although standard regimens may provide inadequate platelet inhibition compared to non-diabetics.